Visus Therapeutics, Inc. (doing business as BRIMOCHOL) is an American company located in Seattle, WA, with domestic subsidiaries. The firm operates as pharmaceutical company. It was founded by Rhett M. Schiffman and Benjamin Scot Bergo. Benjamin Scot Bergo is the CEO, in this role since 2019.\nThe company says this about itself: With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration.